CL2017000372A1 - Composiciones novedosas, usos y métodos para hacerlas. - Google Patents
Composiciones novedosas, usos y métodos para hacerlas.Info
- Publication number
- CL2017000372A1 CL2017000372A1 CL2017000372A CL2017000372A CL2017000372A1 CL 2017000372 A1 CL2017000372 A1 CL 2017000372A1 CL 2017000372 A CL2017000372 A CL 2017000372A CL 2017000372 A CL2017000372 A CL 2017000372A CL 2017000372 A1 CL2017000372 A1 CL 2017000372A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- make
- novel compositions
- compounds
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
<p>GENERALMENTE, LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE QUINOLONA NOVEDOSOS Y COMPOSICIÓN FARMACÉUTICA DE LOS MISMOS QUE PUEDEN INHIBIR LA PROLIFERACIÓN CELULAR Y/O INDUCIR LA APOPTOSIS CELULAR. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA PREPARAR TALES COMPUESTOS Y COMPOSICIONES, Y MÉTODOS PARA FABRICAR Y USAR EL MISMO.</p>
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461991282P | 2014-05-09 | 2014-05-09 | |
| US201462050202P | 2014-09-15 | 2014-09-15 | |
| US201462054054P | 2014-09-23 | 2014-09-23 | |
| US201562128208P | 2015-03-04 | 2015-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000372A1 true CL2017000372A1 (es) | 2017-09-08 |
Family
ID=54393079
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002798A CL2016002798A1 (es) | 2014-05-09 | 2016-11-04 | Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón. |
| CL2017000372A CL2017000372A1 (es) | 2014-05-09 | 2017-02-13 | Composiciones novedosas, usos y métodos para hacerlas. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002798A CL2016002798A1 (es) | 2014-05-09 | 2016-11-04 | Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9512123B2 (es) |
| EP (2) | EP3219716B1 (es) |
| JP (2) | JP6188179B2 (es) |
| KR (3) | KR102044648B1 (es) |
| CN (2) | CN106459068B (es) |
| AU (3) | AU2015255738C1 (es) |
| BR (1) | BR112016026150B1 (es) |
| CA (2) | CA2974960A1 (es) |
| CL (2) | CL2016002798A1 (es) |
| CY (1) | CY1120935T1 (es) |
| DK (1) | DK3140305T3 (es) |
| EA (1) | EA034235B1 (es) |
| EC (3) | ECSP16088687A (es) |
| ES (1) | ES2679628T3 (es) |
| HR (1) | HRP20181105T1 (es) |
| HU (1) | HUE039733T2 (es) |
| IL (2) | IL248638B (es) |
| LT (1) | LT3140305T (es) |
| MX (1) | MX388752B (es) |
| NI (1) | NI201600168A (es) |
| NZ (1) | NZ725917A (es) |
| PE (2) | PE20170678A1 (es) |
| PH (2) | PH12016502213B1 (es) |
| PL (1) | PL3140305T3 (es) |
| PT (1) | PT3140305T (es) |
| RS (1) | RS57493B1 (es) |
| SG (2) | SG10201703658SA (es) |
| SI (1) | SI3140305T1 (es) |
| SM (1) | SMT201800418T1 (es) |
| TR (1) | TR201809990T4 (es) |
| UA (1) | UA117182C2 (es) |
| WO (1) | WO2015172123A1 (es) |
| ZA (1) | ZA201607573B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CN110709400A (zh) * | 2017-03-28 | 2020-01-17 | 皮梅拉股份有限公司 | Pol1抑制剂的新型晶体形式 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CN112300173B (zh) * | 2019-07-30 | 2021-10-01 | 上海凌达生物医药有限公司 | 一类含氮多环类化合物、制备方法和用途 |
| TW202115024A (zh) | 2019-08-14 | 2021-04-16 | 美商英塞特公司 | 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物 |
| CN110606850A (zh) * | 2019-09-11 | 2019-12-24 | 中山大学 | 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用 |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US20240254117A1 (en) * | 2020-12-27 | 2024-08-01 | Shanghai Ringene Biopharma Co., Ltd. | Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN113416197B (zh) * | 2021-08-25 | 2021-12-28 | 北京鑫开元医药科技有限公司 | 甲酰胺类衍生物、制备方法、药物组合物及应用 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN114276354B (zh) * | 2022-01-07 | 2023-06-02 | 中山大学 | 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用 |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7709746A (nl) * | 1976-09-09 | 1978-03-13 | Hoechst Ag | Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen. |
| DE2929414A1 (de) * | 1979-07-20 | 1981-02-05 | Hoechst Ag | Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung |
| DE3502689A1 (de) * | 1985-01-26 | 1986-07-31 | Hoechst Ag, 6230 Frankfurt | Elektrophotographisches aufzeichnungsmaterial |
| EP0647226B1 (de) * | 1992-06-22 | 1997-09-03 | Boehringer Ingelheim Kg | 9-AMINO-PYRIDAZINO 4',5' : 3,4]PYRROLO- 2,1-a]ISOCHINOLINE UND DEREN VERWENDUNG FÜR DIE HERSTELLUNG VON PHARMAZEUTISCHEN ZUBEREITUNGEN |
| DE19509043A1 (de) * | 1995-03-03 | 1996-09-05 | Bayer Ag | Cyanierung von Doppelbindungssystemen |
| HUP0302925A3 (en) * | 2000-10-03 | 2004-10-28 | Bristol Myers Squibb Co | Amino-substituted tetracyclic compouds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
| US7354916B2 (en) | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
| US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
| WO2004091504A2 (en) | 2003-04-07 | 2004-10-28 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
| EP1802306A2 (en) | 2004-09-17 | 2007-07-04 | Cylene Pharmaceuticals, Inc. | Quinolone analog as cell proliferation inhibitors |
| US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
| ITMI20042476A1 (it) * | 2004-12-23 | 2005-03-23 | Cell Therapeutics Europe Srl | Derivati indolici ad attivita' antitumorale |
| EP1874731A4 (en) | 2005-04-15 | 2009-08-05 | Cylene Pharmaceuticals Inc | CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION |
| WO2007019295A1 (en) | 2005-08-05 | 2007-02-15 | Cylene Pharmaceuticals, Inc. | Methods of preparing quinolone analogs |
| WO2007038215A1 (en) * | 2005-09-22 | 2007-04-05 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| US8142909B2 (en) | 2006-02-10 | 2012-03-27 | Universal Display Corporation | Blue phosphorescent imidazophenanthridine materials |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| WO2008060693A2 (en) * | 2006-05-17 | 2008-05-22 | Cylene Pharmaceuticals, Inc. | Tetracyclic imidazole analogs |
| DE102006051796A1 (de) | 2006-11-03 | 2008-05-08 | Merck Patent Gmbh | Triaza-benzo[e]azulenderivate |
| CA2701630C (en) * | 2007-10-05 | 2016-10-25 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| ATE542813T1 (de) | 2008-08-06 | 2012-02-15 | Pfizer | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren |
| US8368062B2 (en) | 2008-11-03 | 2013-02-05 | Lg Chem, Ltd. | Nitrogen-containing heterocyclic compound and organic electronic device using the same |
| US8124770B2 (en) | 2009-04-01 | 2012-02-28 | Beatriz Zayas | Fluorescent cellular markers |
| CN101781312B (zh) * | 2009-12-30 | 2012-09-26 | 中国科学院广州生物医药与健康研究院 | 一种吲哚衍生物的合成方法 |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| US20140086839A1 (en) * | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| KR101561730B1 (ko) * | 2012-02-06 | 2015-10-22 | 주식회사 엘지화학 | 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자 |
-
2015
- 2015-05-09 CN CN201580031811.0A patent/CN106459068B/zh active Active
- 2015-05-09 DK DK15790016.8T patent/DK3140305T3/en active
- 2015-05-09 CA CA2974960A patent/CA2974960A1/en not_active Abandoned
- 2015-05-09 JP JP2016575683A patent/JP6188179B2/ja active Active
- 2015-05-09 KR KR1020187030648A patent/KR102044648B1/ko active Active
- 2015-05-09 SM SM20180418T patent/SMT201800418T1/it unknown
- 2015-05-09 AU AU2015255738A patent/AU2015255738C1/en active Active
- 2015-05-09 SI SI201530315T patent/SI3140305T1/sl unknown
- 2015-05-09 HR HRP20181105TT patent/HRP20181105T1/hr unknown
- 2015-05-09 PE PE2017000488A patent/PE20170678A1/es unknown
- 2015-05-09 ES ES15790016.8T patent/ES2679628T3/es active Active
- 2015-05-09 US US14/708,230 patent/US9512123B2/en active Active
- 2015-05-09 BR BR112016026150-0A patent/BR112016026150B1/pt active IP Right Grant
- 2015-05-09 PE PE2016002189A patent/PE20170131A1/es unknown
- 2015-05-09 UA UAA201612474A patent/UA117182C2/uk unknown
- 2015-05-09 SG SG10201703658SA patent/SG10201703658SA/en unknown
- 2015-05-09 SG SG11201609171XA patent/SG11201609171XA/en unknown
- 2015-05-09 EA EA201692269A patent/EA034235B1/ru unknown
- 2015-05-09 WO PCT/US2015/030046 patent/WO2015172123A1/en not_active Ceased
- 2015-05-09 RS RS20180827A patent/RS57493B1/sr unknown
- 2015-05-09 NZ NZ725917A patent/NZ725917A/en unknown
- 2015-05-09 KR KR1020177009732A patent/KR20170042821A/ko not_active Ceased
- 2015-05-09 CA CA2948173A patent/CA2948173C/en active Active
- 2015-05-09 PL PL15790016T patent/PL3140305T3/pl unknown
- 2015-05-09 CN CN201710268769.5A patent/CN106995443B/zh active Active
- 2015-05-09 MX MX2016014555A patent/MX388752B/es unknown
- 2015-05-09 KR KR1020167033915A patent/KR101890505B1/ko active Active
- 2015-05-09 EP EP17166200.0A patent/EP3219716B1/en active Active
- 2015-05-09 LT LTEP15790016.8T patent/LT3140305T/lt unknown
- 2015-05-09 HU HUE15790016A patent/HUE039733T2/hu unknown
- 2015-05-09 EP EP15790016.8A patent/EP3140305B1/en active Active
- 2015-05-09 PT PT157900168T patent/PT3140305T/pt unknown
- 2015-05-09 TR TR2018/09990T patent/TR201809990T4/en unknown
-
2016
- 2016-10-31 IL IL248638A patent/IL248638B/en active IP Right Grant
- 2016-11-02 ZA ZA2016/07573A patent/ZA201607573B/en unknown
- 2016-11-04 CL CL2016002798A patent/CL2016002798A1/es unknown
- 2016-11-07 NI NI201600168A patent/NI201600168A/es unknown
- 2016-11-08 PH PH12016502213A patent/PH12016502213B1/en unknown
- 2016-11-17 EC ECIEPI201688687A patent/ECSP16088687A/es unknown
- 2016-12-26 JP JP2016251010A patent/JP2017101038A/ja not_active Withdrawn
-
2017
- 2017-02-13 CL CL2017000372A patent/CL2017000372A1/es unknown
- 2017-03-31 AU AU2017202145A patent/AU2017202145B2/en active Active
- 2017-04-07 PH PH12017500660A patent/PH12017500660A1/en unknown
- 2017-05-23 EC ECIEPI201731525A patent/ECSP17031525A/es unknown
- 2017-06-13 AU AU2017203955A patent/AU2017203955A1/en not_active Abandoned
-
2018
- 2018-06-29 EC ECSENADI201849420A patent/ECSP18049420A/es unknown
- 2018-07-18 CY CY181100752T patent/CY1120935T1/el unknown
-
2019
- 2019-01-24 IL IL264454A patent/IL264454A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000372A1 (es) | Composiciones novedosas, usos y métodos para hacerlas. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2017000576A1 (es) | Inhibidores de mk2 y sus usos | |
| PH12018500718A1 (en) | Compounds useful as modulators of trpm8 | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| CR20190566A (es) | Inhibidores de quinasay usos de los mismos | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| CL2016002877A1 (es) | Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos. | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| CL2017001046A1 (es) | Inhibidoes del bromodominio | |
| CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
| CO2017011152A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca. | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| MX373320B (es) | Compuestos inhibidores de pde2. | |
| ECSP18018793A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| MX2017008373A (es) | Compuestos, composiciones y metodos. | |
| CU20180044A7 (es) | Derivados novedosos de diamino piridina | |
| CU20170134A7 (es) | 2-tiopirimidinonas | |
| MX376504B (es) | Composiciones para el tratamiento de enfermedades renales y/o hepaticas. | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY37009A (es) | Formulaciones granuladas de giberelina |